AI assistant
Xlife Sciences AG Regulatory Filings 2021
1041_rns_2021-10-07_e16ce171-776c-4904-a437-7be427ede645.html
Regulatory Filings
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 3406O
Xlife Sciences AG
07 October 2021
Xlife Sciences AG: Successful license deal with Vitese Trading GmbH
DGAP-Media / 07.10.2021 / 09:05
MEDIA INFORMATION
Xlife Sciences AG (XLS DE): Successful license deal with Vitese Trading GmbH
Inflamed pharma GmbH signs license agreement with Vitesse Trading GmbH
The Xlife-project company inflamed pharma GmbH has concluded an exclusive license agreement with the Austrian Vitesse Trading GmbH for the sale of its active ingredient ProcCluster(R). ProcCluster(R) has a positive effect on the course of an infection with SARS-CoV-2 and flu viruses due to its anti-inflammatory characteristics. The agreement applies to five European countries and is associated to minimum purchase quantities.
With the license agreement, Vitesse Trading GmbH has secured the exclusive rights for the distribution of ProcCluster(R) in Austria, Hungary, Slovenia, Croatia and Bulgaria. There is also the opportunity of extending the contract to other countries. Treatment with ProcCluster(R) demonstrated promising results in more than 50 treated COVID infections, long COVID or post-COVID vaccination reactions. Adverse Reactions, such as chronic tiredness, exhaustion, persistent lack of energy, cognitive deficits, pain in the limbs, joints and muscles, loss of smell and or taste, dizziness, anxiety syndrome and shortness of breath were alleviated. Hospitalizations could be avoided. According to the management, the aim is to make ProcCluster(R) available to as many patients as possible in the fight against COVID-19. Therefore, inflamed pharma GmbH is in talks with other licensees.
About Xlife Sciences AGXlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
About Vitesse Trading GmbH
Vitesse Trading is an Austrian company that specializes in the distribution of medical products. The current primary goal of Vitesse is to support healthcare facilities in combating the causes and consequences of COVID-10.
For media inquiries:Dennis Lennartz, Head Investor Relations, Xlife Sciences AG, Tel. +41 44 385 84 60, [email protected]
For scientific inquiries:Dr. Frank Plöger, Chief Scientific Officer, Xlife Sciences AG, Tel. +41 44 385 84 62,
End of Media Release
Issuer: Xlife Sciences AG
Key word(s): Industry
07.10.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Xlife Sciences AG |
| Klausstrasse 19 | |
| 8008 Zürich | |
| Switzerland | |
| Phone: | 0041 44 385 84 60 |
| E-mail: | [email protected] |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| WKN: | A2PK6Z |
| Listed: | Regulated Unofficial Market in Frankfurt, Munich |
| EQS News ID: | 1238970 |
| End of News | DGAP Media |
1238970 07.10.2021
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRADDLBBFBLEFBL